Exelixis reports interim data of XL184 for metastatic castration-resistant prostate c

[News]

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

More... (http://www.news-medical.net/news/20101118/Exelixis-reports-interim-data-of-XL184-for-metastatic-castration-resistant-prostate-cancer.aspx)